首页> 外文期刊>Journal of aerosol medicine and pulmonary drug delivery >Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial
【24h】

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

机译:高渗盐水溶液对支气管扩张患者的痰液祛痰及其安全性曲线的影响:随机交叉试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum quantity with better safety profile than HS alone in patients with bronchiectasis. Methods: In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA +7%HS; and 0.9% isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration. Participants inhaled each solution across four consecutive sessions. All sessions, except on session 3, also included 30 minutes of airway clearance technique. A 7-day washout period was applied. Sputum weight was collected during the sessions (primary outcome) as well as during a 24-hour follow-up. The Leicester Cough Questionnaire (LCQ) and lung function were measured before/after each treatment arm. Safety was assessed by the monitoring of adverse events (AEs). Results: Twenty-eight patients with bronchiectasis (mean age of 64.0 (17.9) and FEV1% 60.9 (24.6) of predicted) were recruited. HS and HA+HS promoted similar expectoration during sessions, both being greater than IS [median difference HS vs. IS 3.7g (95% CI 0.5-6.9); HA+HS vs. IS 3.2g (95%CI 0.5-5.9)]. Sputum expectorated exclusively during the ACT period was similar across all treatment arms [HS vs. IS -0.3g (95% CI -1.7 to 0.9); HA+HS vs. IS 0.0g (95% CI -1.3 to 1.4); HS vs. HA+HS 0.0g (95% CI -1.2 to 0.4)]. Sputum collected over the 24-hour follow-up tended to be lower for HS and HA+HS compared with IS [HS vs. IS -1.7g (95% CI -4.2 to 0.0); HA+HS vs. IS -1.1g (95%CI -3.6 to 0.7)]. No differences in LCQ or lung function were observed. Most severe AEs were reported using HS. Conclusion: HS and HA+HS were more effective on sputum expectoration than IS in patients with bronchiectasis, reporting HA+HS better safety profile than HS.
机译:背景:透明质酸加高渗盐水(HA + HS)作为支气管扩张患者的粘液治疗的作用仍然未知。该研究评估了HA + HS溶液是否增强了与支气管扩张患者单独具有比HS更好的安全性曲线的相似痰液。方法:在这种双盲随机交叉试验中,三种溶液(7%HS; 0.1%HA + 7%HS;和0.9%等膦盐,是0.9%的等渗盐水),与支气管扩张和慢性痰祛痰。参与者在连续四个会议上吸入每个解决方案。所有会议除外3,还包括30分钟的航空通风技术。应用了7天的洗涤期。在会话期间(主要结果)以及24小时后续行动期间收集痰重量。在每次治疗臂之前/之后测量Leicester咳嗽问卷(LCQ)和肺功能。通过监测不良事件(AES)来评估安全性。结果:招募了二十八名支气管扩张患者(平均年龄为64.0(17.9)和预测的FEV1%60.9(24.6)。 HS和HA + HS在会话期间促进了类似的咳痰,两者大于[中位差HS与3.7g(95%CI 0.5-6.9); HA + HS与3.2g(95%CI 0.5-5.9)]。所有治疗臂的ACT期间仅在动作期间分泌的痰液相似[HS对 - 0.3g(95%CI -1.7至0.9); HA + HS与0.0克(95%CI -1.3至1.4); HS与HA + HS 0.0G(95%CI -1.2至0.4)]。与HS和HA + Hs相比,在24小时后续的24小时后续往下进行的痰液与[HS Vs.]为-1.7g(95%CI -4.2至0.0); HA + HS与-1.1g(95%CI -3.6至0.7)]]。没有观察到LCQ或LUNG功能的差异。使用HS报告最严重的AES。结论:HS和HA + HS对痰祛痰比支气管扩张患者更有效,报告HA + HS更好的安全性曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号